NovaVive’s canine anticancer immunotherapeutic agent to enter clinical trials
February 28, 2019
NovaVive says it is starting clinical trials at Iowa State University (ISU) College of Veterinary Medicine on a new canine anticancer immunotherapeutic. The anticancer treatment, Immunocidin, has received regulatory approval in Canada and the United States to treat mammary tumours. The study will observe dogs with stage I or stage II splenic hemangiosarcoma (HSA) who… Continue reading...